Here are the Form 4 insider transactions from ANI Pharmaceuticals, Inc. (ANIP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ANIP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIP filings page.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported two equity transactions in company common stock. On February 26, 2026, he received a grant of 22,233 restricted shares at $77.15 per share, which will vest in four equal annual installments starting on the first anniversary of that date. On February 28, 2026, 2,773 shares at $73.90 per share were disposed of for tax withholding in connection with the vesting of 6,079 previously granted restricted shares. After these transactions, he directly owned 189,543 common shares.
ANI Pharmaceuticals executive Christopher Mutz reported an open-market sale of company stock. On the reported date, he sold 5,323 shares of ANI Pharmaceuticals common stock at a weighted average price of $78.02 per share, with individual trade prices ranging from $77.20 to $78.58.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. After this sale, Mutz directly holds 84,840 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals senior vice president and chief human resources officer Krista Davis sold a total of 3,814 shares of Common Stock in open‑market transactions. She sold 2,084 shares at a weighted average price of $77.53 on February 19, 2026 and 1,730 shares at $77.99 on February 20, 2026. The sales were executed under a Rule 10b5‑1 trading plan adopted on September 18, 2025, and she held 49,263 shares directly after the most recent sale.
Rowland Thomas Andrew reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 1,051 shares at a weighted average price of $77.00 per share. Following the reported transactions, holdings were 38,109 shares.
ANI Pharmaceuticals executive Christopher Mutz, Head of Rare Disease, reported share transactions in company common stock. On February 12, he completed an open-market sale of 7,032 shares at a weighted average price of $76.55 under a Rule 10b5-1 trading plan adopted on June 16, 2025. That same day, 3,173 shares and, on February 14, 2,403 shares were withheld to cover tax liabilities tied to vesting of previously granted restricted stock awards, at prices of $76.70 and $77.36, respectively. Following these transactions, Mutz directly held 90,163 ANI Pharmaceuticals shares.
Lalwani Nikhil reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 21,986 shares at a weighted average price of $77.01 per share. Following the reported transactions, holdings were 358,574 shares.
ANI Pharmaceuticals SVP Ori Gutwerg reported tax-withholding share transactions tied to restricted stock vesting. On February 12, 1,775 shares of common stock were withheld at $76.7 per share, and on February 14, 1,888 shares were withheld at $77.36 per share.
These dispositions were made to cover tax obligations in connection with the vesting of 3,917 and 3,691 previously granted restricted shares. After these transactions, Gutwerg directly owned 76,094 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP Chad Gassert reported tax-withholding share transactions in company stock. On February 12, 2026, 1,608 shares of common stock were disposed of at $76.70 per share as a tax-withholding disposition tied to restricted stock vesting. On February 14, 2026, a further 1,717 shares were disposed of at $77.36 per share, also to cover tax obligations on vesting restricted stock awards.
After these transactions, Gassert directly beneficially owned 66,021 shares of ANI Pharmaceuticals common stock and indirectly beneficially owned 158,490 shares held by Chali Properties LLC, over which he holds voting and dispositive power.
ANI Pharmaceuticals’ SVP and Chief HR Officer Krista Davis reported tax-related share dispositions connected to restricted stock vesting. On February 12, 2026, 1,180 shares of common stock were disposed of at $76.70 per share for tax withholding, leaving 54,367 shares held directly. On February 14, 2026, a further 1,290 shares were disposed of at $77.36 per share for tax withholding, resulting in 53,077 common shares held directly afterward. The footnotes state these were shares withheld for taxes upon vesting of 3,264 and 3,020 restricted stock shares previously granted.
ANI Pharmaceuticals senior executive Meredith W. Cook reported several stock transactions involving company common shares. On February 13, 2026, she sold 500 shares of ANI Pharmaceuticals common stock in an open-market sale at an average price of $76.8 per share under a Rule 10b5-1 trading plan adopted on September 15, 2025.
On February 12 and February 14, 2026, a total of 3,313 shares were withheld to cover tax obligations in connection with the vesting of previously granted restricted stock awards, at prices of $76.7 and $77.36 per share, respectively. After these transactions, she directly owned 67,550 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported tax-withholding share dispositions related to restricted stock vesting. On February 12, 2026, 2,829 shares of common stock were withheld at $76.7 per share to cover taxes on 6,202 vested restricted shares. On February 14, 2026, 2,448 shares were withheld at $77.36 per share to cover taxes on 5,368 vested restricted shares. After these non-market transactions, Carey directly beneficially owned 170,083 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported a tax-related share disposition. On February 11, 2026, 5,503 shares of ANI Pharmaceuticals common stock were withheld at $76.25 per share to cover taxes in connection with the vesting of 16,210 performance stock units, a grant originally reported on April 6, 2023. After this non‑open‑market, tax‑withholding transaction, Carey directly beneficially owns 175,360 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals executive Meredith Cook reported a tax-related share disposition. On February 11, 2026, 3,011 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share to cover tax obligations tied to equity compensation.
The filing explains that these shares were withheld for tax purposes in connection with the vesting of 8,104 performance stock units, previously granted on April 6, 2023. After this tax-withholding transaction, Cook directly beneficially owned 71,363 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP Krista Davis reported a tax-withholding share disposition. On February 11, 2026, 3,017 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share as a tax-withholding disposition related to equity compensation.
The footnote explains that these shares were withheld for tax purposes in connection with the vesting of 8,104 performance stock units, a grant originally reported on April 6, 2023. After this transaction, Davis directly owned 55,547 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP Chad Gassert reported a tax-related share withholding on company stock. On February 11, 2026, 4,269 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share to cover tax obligations tied to the vesting of 11,578 performance stock units previously granted.
After this tax-withholding disposition, Gassert directly beneficially owned 69,346 shares of common stock. He also indirectly beneficially owned an additional 158,490 shares held by Chali Properties LLC, over which he holds voting and dispositive power.
ANI Pharmaceuticals senior vice president Ori Gutwerg reported a tax-related share disposition linked to equity vesting. On 02/11/2026, 4,267 shares of common stock were disposed of at $76.25 per share to cover tax withholding in connection with the vesting of 11,578 performance stock units.
Following this tax-withholding transaction, Gutwerg directly beneficially owned 79,757 shares of ANI Pharmaceuticals common stock. The filing characterizes the transaction as exempt under Rule 16(b)-3 because it relates to equity compensation vesting rather than an open-market trade.
Lalwani Nikhil reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 30,659 shares at a weighted average price of $76.25 per share. Following the reported transactions, holdings were 380,560 shares.
ANI Pharmaceuticals executive Christopher Mutz, Head of Rare Disease, reported a tax-withholding disposition of company stock related to equity compensation. On February 11, 2026, 4,546 shares of ANI Pharmaceuticals common stock were withheld at $76.25 per share to cover taxes.
This withholding was tied to the vesting of 11,578 performance stock units previously granted on April 6, 2023 and is exempt under Rule 16(b)-3. After this transaction, Mutz directly holds 102,771 shares of ANI Pharmaceuticals common stock.
Rowland Thomas Andrew reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 1,762 shares at a weighted average price of $76.25 per share. Following the reported transactions, holdings were 39,160 shares.
Shanmugam Muthusamy reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 2,898 shares at a weighted average price of $76.25 per share. Following the reported transactions, holdings were 89,940 shares.
ANI Pharmaceuticals executive Meredith W. Cook, Senior Vice President, General Counsel and Secretary, reported a small open-market sale of company common stock. On January 13, 2026, she sold 500 shares of ANI Pharmaceuticals common stock at a price of $84.33 per share, as disclosed in a Form 4 insider trading report.
After this transaction, Cook directly beneficially owned 74,374 shares of ANI Pharmaceuticals common stock. The filing notes that this sale was carried out under a pre-established Rule 10b5-1 trading plan that she adopted on September 15, 2025, indicating the trades were scheduled in advance rather than timed at her discretion.
ANI Pharmaceuticals reported an insider stock sale by senior vice president, general counsel and secretary Meredith W. Cook. On December 12, 2025, she sold 400 shares of the companys common stock at $82.32 per share.
After this transaction, Cook directly beneficially owned 74,874 ANI Pharmaceuticals shares. The disclosure states that the sale was carried out under a Rule 10b5-1 trading plan that she adopted on September 17, 2024, indicating the trade was made pursuant to a pre-established plan.